2024 年度独立董事述职报告 （张宪胜） 2024 年度，作为普莱柯生物工程股份有限公司（以下简称"公司"）的独 立董事，本人严格按照《中华人民共和国公司法》《上市公司治理准则》《上市 公司独立董事管理办法》《上海证券交易所股票上市规则》《上海证券交易所上 市公司自律监管指引第 1 号—规范运作》以及《公司章程》《独立董事工作制度》 等有关规定，勤勉尽责，在董事会日常工作及重要决策中忠实履行独立董事的职 责和义务，认真审议各项议案，从公司整体利益出发，维护了公司和全体股东特 别是中小股东的合法权益。现将本人在 2024 年度履职情况报告如下： 一、独立董事的基本情况 1、本人个人简历及独立性情况说明 普莱柯生物工程股份有限公司 本人张宪胜，在职研究生学历，正高级会计师职称、注册会计师。曾担任安 阳钢铁股份有限公司总会计师（财务负责人）、董事会秘书以及安阳钢铁集团有 限责任公司审计部部长、审计与法律事务部部长、财务部部长、财务部总监、安 钢集团一级首席专家等职务。现任公司第五届董事会独立董事、河南清水源科技 股份有限公司独立董事、河南双汇投资发展股份有限公司独立董事职务。 本人自 2023 年 4 月 11 ...

普莱柯生物工程股份有限公司 董事会关于独立董事独立性情况的专项意见 根据中国证券监督管理委员会《上市公司独立董事管理办法》《上海证券交 易所上市公司自律监管指引第 1 号——规范运作》等法律法规、规范性文件的相 关要求，普莱柯生物工程股份有限公司（以下简称"公司"）董事会就公司现任 独立董事曹永长先生、王楚端先生、张宪胜先生的独立性进行评估并出具以下专 项意见： 经核查上述人员的任职经历及其本人签署的相关自查文件，确认公司现任独 立董事曹永长先生、王楚端先生、张宪胜先生未在公司担任除独立董事之外的任 何职务，未在公司主要股东公司担任任何职务，未直接或间接持有公司股份，与 公司、主要股东及实际控制人之间不存在利害关系或其他可能妨碍其进行独立客 观判断的关系，不存在影响独立董事独立性的情况。公司独立董事符合《上市公 司独立董事管理办法》《上海证券交易所股票上市规则》《上海证券交易所上市公 司自律监管指引第 1 号——规范运作》等规定中关于独立董事任职资格及独立性 的要求。 普莱柯生物工程股份有限公司 董 事 会 2025 年 4 月 24 日 ...

普莱柯生物工程股份有限公司 2024 年度独立董事述职报告 （王楚端） 2024 年度，作为普莱柯生物工程股份有限公司（以下简称"公司"）的独 立董事，本人严格按照《中华人民共和国公司法》《上市公司治理准则》《上市 公司独立董事管理办法》《上海证券交易所股票上市规则》《上海证券交易所上 市公司自律监管指引第 1 号—规范运作》以及《公司章程》《独立董事工作制度》 等有关规定，勤勉尽责，在董事会日常工作及重要决策中忠实履行独立董事的职 责和义务，认真审议各项议案，从公司整体利益出发，维护了公司和全体股东特 别是中小股东的合法权益。现将本人在 2024 年度履职情况报告如下： 一、独立董事的基本情况 1、独立董事个人简历及独立性情况说明 本人王楚端，博士学历。历任中国农业大学动物科技学院讲师、副教授、教 授，博士生导师。现任中国畜牧兽医学会养猪学分会理事长、农业农村部生猪遗 传改良计划专家委员会委员、中国畜牧兽医学会动物遗传育种学分会理事、重庆 生猪产业技术研究院有限公司董事、浙江大飞龙动物保健品股份有限公司独立董 事等职务。 本人自 2023 年 4 月 11 日起担任公司第五届董事会独立董事职务，兼任公司 第 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一)股东大会类型和届次 2024年年度股东大会 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 5 月 16 日 14 点 00 分 召开地点：河南省洛阳市洛龙区政和路 15 号公司二楼会议室 证券代码：603566 证券简称：普莱柯 公告编号：2025-015 普莱柯生物工程股份有限公司 关于召开2024年年度股东大会的通知 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 5 月 16 日 至2025 年 5 月 16 日 股东大会召开日期：2025年5月16日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 ...

证券代码：603566 证券简称：普莱柯 公告编号：2025-018 普莱柯生物工程股份有限公司 关于第五届监事会第十二次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 普莱柯生物工程股份有限公司（以下简称"公司"）第五届监事会第十二次会 议于 2025 年 4 月 14 日以当面送达方式发出会议通知，并于 2025 年 4 月 24 日在 洛阳市洛龙区政和路 15 号公司会议室召开。公司监事 3 名，实到 3 人。本次会 议符合《中华人民共和国公司法》和《公司章程》的有关规定，合法有效。 二、监事会会议审议情况 1、关于公司 2024 年度报告全文及摘要的议案 公司 2024 年年度报告的内容与格式符合中国证监会和交易所的各项规定， 能客观公正、真实可靠地反映公司经营成果和财务状况；2024 年年度报告所披 露的信息真实、完整，并承诺不存在虚假记载、误导性陈述或者重大遗漏；未发 现参与公司 2024 年年度报告编制工作人员和其他人员有违反保密规定的行为。 具体内容详见上海证券交易所网站( ...

证券代码：603566 证券简称：普莱柯 公告编号：2025-017 普莱柯生物工程股份有限公司 关于第五届董事会第十八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 普莱柯生物工程股份有限公司（以下简称"公司"）第五届董事会第十八次 会议于 2025 年 4 月 14 日以电子邮件、当面送达等形式发出会议通知，并于 2025 年 4 月 24 日以现场方式在公司会议室召开，出席会议的董事应到 9 人，实际参 加会议的董事 9 人。会议由公司董事长张许科先生主持，符合《公司法》和《公 司章程》的有关规定，会议合法有效。 二、董事会会议审议情况 1、关于公司 2024 年度报告全文及摘要的议案 具体内容详见上海证券交易所网站(www.sse.com.cn)相关公告。 本议案已经公司第五届董事会审计委员会第十三次会议审议通过，同意提交 董事会审议。该事项尚需提交股东大会审议通过。 表决结果：9 票赞成，0 票反对，0 票弃权。 2、关于公司 2024 年度董事会工作报告的议案 该事项尚需提交股东大会审议通过。 表决 ...

证券代码：603566 证券简称：普莱柯 公告编号：2025-010 普莱柯生物工程股份有限公司 关于 2024 年度利润分配预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、利润分配方案内容 经立信会计师事务所（特殊普通合伙）审计，普莱柯生物工程股份有限公司 （以下简称"公司"）2024 年度归属于上市公司股东的净利润为 9,280.65 万元， 截至 2024 年 12 月 31 日，母公司期末可供分配利润为人民币 82,490.18 万元。经 公司第五届董事会第十八次会议决议，公司 2024 年度利润分配方案拟以实施股 权登记日总股本扣除回购专户已回购股份数之后的股本为基数分配利润。本次利 润分配方案如下： 以利润分配方案实施股权登记日总股本扣除回购专户已回购股份数之后的 股本为基数进行分配，向全体股东每 10 股派送现金红利人民币 4 元（含税）。 以截至 2024 年 12 月 31 日的总股本 346,062,273 股扣除回购专户已回购股份数 4,142,900 股后的股本 341, ...

Financial Performance - The company reported a revenue of 1,042,561,095 CNY for 2024, a decrease of 16.77% compared to 1,252,693,603 CNY in 2023[23]. - Net profit attributable to shareholders was 92,806,499.78 CNY, down 46.82% from 174,517,388.93 CNY in the previous year[23]. - Basic earnings per share decreased by 46.00% to 0.27 CNY in 2024 from 0.50 CNY in 2023[24]. - The company's total assets decreased by 5.06% to 3,097,197,622 CNY at the end of 2024, down from 3,262,208,830 CNY at the end of 2023[23]. - The weighted average return on equity fell to 3.51% in 2024, down from 6.31% in 2023, a decrease of 2.80 percentage points[24]. - The net cash flow from operating activities was 268,788,363.47 CNY, a decline of 4.95% compared to 282,777,239.58 CNY in 2023[23]. - The company's operating revenue for the reporting period was approximately ¥1.04 billion, a decrease of 16.77% compared to the previous year[75]. - The revenue from animal pharmaceuticals was approximately CNY 1,005.40 million, a decrease of 18.25% compared to the previous year, with a gross margin of 61.35%[78]. - The revenue from functional health products generated CNY 18.65 million, an increase of 131.93% year-over-year, with a gross margin of 56.51%, reflecting a significant improvement of 23.23 percentage points[78]. - The sales revenue from the top five customers amounted to 86.12 million yuan, accounting for 8.33% of the total annual sales[84]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of RMB 4 per 10 shares (including tax), with an estimated total cash dividend payout of RMB 136,767,749.20[6]. - The total cash dividend amount (including tax) for the recent fiscal year is CNY 189,463,073.43, which accounts for 204.15% of the net profit attributable to ordinary shareholders of the listed company[172]. - The cumulative cash dividend amount (including tax) over the last three fiscal years is CNY 499,553,455.85, with a cumulative repurchase and cancellation amount of CNY 133,545,761.22, totaling CNY 633,099,217.07[174]. - The average annual net profit over the last three fiscal years is CNY 145,048,087.66, resulting in a cash dividend ratio of 436.48%[174]. - The company has established a cash dividend policy that aligns with its operational performance and shareholder interests[168]. Governance and Compliance - The company has received a standard unqualified audit report from Lixin Certified Public Accountants[5]. - The board of directors and supervisory board members have confirmed the authenticity, accuracy, and completeness of the annual report[3]. - The company has not faced any risks that would prevent the majority of directors from ensuring the report's integrity[9]. - The company maintains strict independence from its controlling shareholder, with no interference in financial or operational decisions[142]. - The company has implemented measures to manage insider information, ensuring confidentiality during the preparation of periodic reports[143]. - The company has a robust governance structure, with a clear separation of powers among the shareholders, board of directors, and management[142]. - The company has not reported any significant changes in competitive conditions or conflicts with its controlling shareholder[144]. - The company has not faced any claims or administrative penalties related to social insurance and housing fund violations during the reporting period[198]. Research and Development - R&D expenditure for 2024 reached CNY 106 million, accounting for 10.17% of total revenue, with 23 invention patents applied and 12 granted, including 2 international patents[38]. - The company achieved significant progress in developing strategic products, with the avian influenza (H5 + H7) vaccine passing initial review for new veterinary drug registration[39]. - The company is focusing on research and development of new vaccines and treatments for livestock diseases, enhancing its market position[107]. - The company has ongoing research projects focused on innovative vaccine technologies, including multi-valent vaccines and new chemical structure drugs[102]. - The company has submitted several products for regulatory approval, including a pig circovirus inactivated vaccine with an approval number valid until December 11, 2029[105]. - The company has received 8 clinical trial approvals in 2024, including a five-in-one inactivated vaccine for chicken Newcastle disease, infectious bronchitis, avian influenza (H9 subtype), and avian adenovirus (I group, type 4)[107]. Market and Competitive Landscape - The company faced challenges due to a decline in effective demand and increased competition in the animal health industry, impacting profitability[35]. - The company is focusing on the pet vaccine and pharmaceutical market, targeting key marketing areas such as pet hospitals and breeding farms to increase market penetration and share[134]. - The company is actively pursuing an "internationalization" strategy, focusing on overseas market development and technical cooperation, aiming for comprehensive output in products, technology, and capital[128]. - The company is committed to continuous innovation in response to major animal diseases and key technological advancements in the industry[64]. - The regulatory environment is tightening with new requirements for veterinary drug registration and animal disease prevention measures set to be implemented in 2024[51][52]. Environmental Responsibility - The company invested CNY 25,753,900 in environmental protection during the reporting period[180]. - The company has established environmental protection mechanisms and has been recognized as a key pollutant discharge unit by environmental authorities[181]. - All pollution prevention facilities are operating well, ensuring compliance with pollutant discharge standards[184]. - The company has completed environmental impact assessments for all existing and ongoing projects, obtaining necessary approvals[185]. - There were no administrative penalties received due to environmental issues during the reporting period[188]. Employee and Talent Management - The total number of employees in the company and its main subsidiaries is 1,551, with 820 in the parent company and 731 in subsidiaries[164]. - The company has a performance-based salary incentive system that focuses on operational efficiency and aims to enhance team motivation[165]. - The company has identified 9 PhD holders, 213 Master's degree holders, and 491 Bachelor's degree holders among its employees, indicating a strong educational background[164]. - The company is conducting a "Talent Theme Month" initiative to identify and nurture high-potential employees for sustainable business development[167]. - The company is continuously improving its talent development system to support core business areas and ensure sustainable growth[167]. Strategic Initiatives - The company has established a comprehensive sales network covering most regions of the country, enhancing collaboration with direct customers and distributors[72]. - The company is implementing a comprehensive management system to enhance cost control and operational efficiency, focusing on procurement, production, and finished product management[131]. - The company has established strategic partnerships with suppliers and customers, enhancing cooperation and resource sharing to provide high-quality products and services[191]. - The company is committed to building a harmonious labor relationship by addressing employees' reasonable needs and providing support during difficulties[190].

Financial Performance - The company's revenue for Q1 2025 was CNY 278,619,332.69, representing an increase of 18.32% compared to CNY 235,489,193.20 in the same period last year[4] - Net profit attributable to shareholders was CNY 52,907,653.44, a significant increase of 93.75% from CNY 27,307,052.31 year-on-year[4] - The basic earnings per share doubled to CNY 0.16 from CNY 0.08, reflecting a 100% increase[4] - Total operating revenue for Q1 2025 reached ¥278,619,332.69, an increase of 18.3% compared to ¥235,489,193.20 in Q1 2024[18] - Net profit for Q1 2025 was ¥52,907,653.44, representing a significant increase of 93.9% from ¥27,307,052.31 in Q1 2024[19] - The total comprehensive income for the period was CNY 52,907,653.44, compared to CNY 27,307,052.31 in the previous period, representing an increase of 93.8%[20] - Basic and diluted earnings per share were both CNY 0.16, doubling from CNY 0.08 in the same quarter last year[20] Cash Flow - The net cash flow from operating activities reached CNY 46,895,605.48, a remarkable turnaround from a negative CNY 4,394,457.00 in the previous year, marking a 1,167.15% increase[4] - Cash flow from operating activities generated a net cash inflow of CNY 46,895,605.48, a significant recovery from a net outflow of CNY -4,394,457.00 in the previous year[23] - The total cash outflow from operating activities was CNY 245,693,694.66, compared to CNY 264,020,981.82 in the same quarter last year, showing a decrease of 6.9%[23] - The net cash outflow from investing activities was CNY -24,489,008.23, an improvement compared to CNY -95,695,591.48 in the same quarter last year[23] - The company reported cash inflows from investment activities of CNY 146,449,038.01, down from CNY 298,979,127.45 in the previous year[23] - The company incurred CNY 17,768,610.62 in cash outflows related to financing activities, which is the same amount as the previous year[24] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,094,448,195.34, a slight decrease of 0.09% from CNY 3,097,197,622.41 at the end of the previous year[5] - Total liabilities decreased to ¥415,448,637.04 as of March 31, 2025, compared to ¥471,105,717.55 at the end of 2024, indicating a reduction of approximately 11.8%[16] - The company's cash and cash equivalents increased to ¥228,903,392.66 from ¥205,256,440.02, marking an increase of 11.5%[13] - Inventory levels decreased to ¥185,212,115.41 from ¥192,602,118.07, a decline of 3.9%[14] - The company's equity attributable to shareholders increased by 2.01% to CNY 2,678,999,558.30 from CNY 2,626,091,904.86[5] - The total equity attributable to shareholders increased to ¥2,678,999,558.30 from ¥2,626,091,904.86, showing a growth of 2.0%[16] Revenue Sources - Revenue from biological products was CNY 196,031,056.20, up 16.82% year-on-year, with significant growth in poultry vaccines by 33.80%[7] - Total operating costs for Q1 2025 were ¥218,366,570.65, up from ¥205,179,343.23 in Q1 2024, reflecting a year-over-year increase of 6.0%[18] - The company reported an operating profit of ¥61,891,227.30 for Q1 2025, compared to ¥31,185,610.68 in Q1 2024, reflecting a growth of 98.5%[19] Shareholder Information - As of the end of the reporting period, the total number of common shareholders was 17,256, with the largest shareholder holding 31.58% of the shares[10] - The company did not report any net profit from subsidiaries prior to consolidation, consistent with the previous period[20] Investment and Development - The company reported a 35.24% increase in construction in progress, primarily due to increased investment in the Huizhong Animal Health Chemical Preparation Industrialization Project[8] - The company's investment income decreased by 290.21%, mainly due to changes in the profits and losses of associated companies[8] - Research and development expenses for Q1 2025 were ¥20,918,388.92, slightly up from ¥20,460,399.77 in Q1 2024, indicating a focus on innovation[19]

■ 普莱柯生物工程股份有限公司 关于子公司获得新兽药注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 根据《兽药管理条例》和《兽药注册办法》规定，经农业农村部审查，批准普莱柯生物工程股份有限公 司（以下简称"公司"）全资子公司洛阳惠中兽药有限公司（以下简称"惠中兽药"）与济南领派生物医药 科技有限公司等单位联合申报的"青霉素V钾可溶性粉"为新兽药，并于2025年4月10日公示了核发《新 兽药注册证书》（中华人民共和国农业农村部公告第899号）事项。详情如下： 一、新兽药的基本信息 二、新兽药研究开发情况及相关市场背景情况 该新兽药为子公司惠中兽药与济南领派生物医药科技有限公司等单位联合开发，农业农村部于2025年4 月10日公告核发新兽药注册证书。 鸡球虫病是一种急性流行性寄生虫病，其发病率极高，分布范围广，危害严重，给养禽业带来了严重的 经济损失。感染球虫病后，产气荚膜梭菌等厌氧菌通过鸡损伤的肠道组织粘膜进入体内，引发鸡坏死性 肠炎。目前治疗鸡球虫病的主要药物长期使用会导致球虫产生耐药性，且价格昂贵。青霉素V钾 ...